According to the haemostatic agent’s review1 article, an ideal haemostatic agent would achieve haemostasis and show other potential benefits including:
“better visualization of the surgical area, shorter operative times, decreased requirement for transfusions, better management of an anticoagulated patient, decreased wound healing time and overall improvement in patient recovery time”.
Based on self-assembling peptide technology, 3-D Matrix has obtained CE mark approval for the surgical haemostatic agent, PuraBond, which has multiple unique features that distinguish it from competitors and make it highly suitable for cardiac surgery.
PuraBond is indicated for haemostasis in the following situations encountered during surgery or endoscopic procedure, when hemostasis by ligation or stand means is insufficient or impractical: 2
Bleeding from small blood vessels and oozing from capillaries of the parenchyma and surrounding tissues of solid organic
Oozing from vascular anastomoses to native or artificial vessels, on the surface of blood vessels and surrounding tissues
1. Comparison of hemostatic agents used in vascular surgery; Krishna S. Vyas, Sibu P. Saha; Expert Opin Biol Ther. 2013 December; 13(12): 1663–1672. 2. PuraBond IFU-009 Rev 2 / IFU-014 Rev 2
Collaboration Opportunities
Our R&D teams are always exploring new innovations and indications to expand our products so that we continue providing healthcare professionals with better services and patient outcomes. If you are interested in collaborating with us, please get in touch.
Discover peptides
Learn more about PuraBond, its synthetic self-assembling peptide (SAP) composition, and the benefits this brings in practice.
